Clinical trials, expanded access and right to try: what differs?

When standard treatment is not helping enough, an experimental option can feel like a door opening. The language around that door is often confusing: clinical trial, compassionate use, expanded access, right to try. Understanding these terms helps a patient and clinician work out what is possible and what the choice would involve.

Start with the person’s health goal. What condition is being treated, what benefit is hoped for, and what evidence supports that hope? The route to treatment matters because it determines who can take part, who reviews the proposal and who is responsible for care.

A clinical trial is a way to learn

A clinical trial is designed to answer a research question. Its plan sets out who can join, what treatment they may receive, what will be measured and how they will be monitored. Some trials assign people randomly to different groups. Joining therefore does not always mean receiving the experimental treatment. [1]

Early trials often concentrate on dose and initial safety. Later studies usually test benefits in larger groups. Completing an early trial is an important step, but it cannot settle every question about rare harms or long-term health. A study of a particular eye disease, for example, cannot establish whole-body rejuvenation.

Ethics review provides another layer of protection. An institutional review board, usually shortened to IRB, examines whether participants’ rights and welfare are adequately protected. Its review is valuable, but it is not a conclusion that the treatment works. [2]

A listing in the US clinical-trial registry can help you find the study team and understand the plan. A listing alone is not government endorsement of the treatment. Confirm eligibility and current recruitment with the named team, and ask what visits, travel and costs participation would involve. Research costs and ordinary medical care may be paid for differently. [3] [4]

Expanded access puts treatment first

Expanded access, sometimes called compassionate use, can allow treatment outside a trial for someone with a serious or immediately life-threatening condition who has no satisfactory alternative and cannot obtain the product through a trial. The possible benefit must justify the risks, and access must not undermine the research needed to develop the treatment. [5] [6]

The process brings together several people. A physician agrees to manage the patient’s care. The manufacturer agrees to supply the product. FDA reviews whether the proposed use may proceed, and an ethics board reviews the plan and consent. Special procedures exist for emergencies and for individual-patient requests. [5] [6]

This can be a meaningful option when choices are limited. It still involves an investigational treatment, with uncertain benefits and potentially serious harms. The company may be unable or unwilling to supply it, and insurance may not cover all treatment and care costs. Those practical questions belong in the discussion early.

What “right to try” means

Federal right to try is a separate US framework for patients with a life-threatening condition who have exhausted approved options and cannot participate in a trial involving the eligible drug. It requires physician certification and written informed consent. [7]

The drug must meet its own conditions: it must have completed a phase 1 trial, remain unapproved, and meet requirements for an active development or application pathway. A product on an FDA clinical hold does not qualify. The label “experimental” is not enough.

Unlike expanded access, federal right to try does not involve FDA review of each request or federally required IRB review. The manufacturer still decides whether to supply the drug and must report use and serious adverse events. The name does not create a guarantee of treatment, payment or benefit. [7]

For someone interested in longevity, a crucial distinction is that a wish to slow aging does not by itself meet the serious-disease and other eligibility requirements of these access pathways.

State laws and treatment abroad

Headlines about a new state law can sound like a new treatment has become approved. The reality is more specific. Montana created a licensing framework for experimental treatment centers, with rules taking effect in July 2026. These cover matters such as patient agreements, records and safety oversight. They are not FDA approval of every intervention a center might propose. [8] [9]

Florida has a different provision addressing specified stem-cell therapy in orthopedics, wound care and pain management, with requirements for sourcing, consent and advertising. It does not provide a blanket authorization for every product marketed for regeneration or anti-aging. State provisions must be considered alongside applicable federal requirements. [10]

Treatment abroad also covers very different situations: established care in another health system, a regulated trial or a commercially marketed experiment. Ask about the exact product and local authorization, and make a plan for complications and follow-up after returning home. Insurance, access to records and continuity of care deserve as much attention as the journey itself. [11]

Receiving treatment in another country and importing a product into the United States are separate issues. FDA generally prohibits personal importation of unapproved drugs, with limited enforcement discretion in specific circumstances. An overseas offer does not create general permission to order a product for use at home. [12]

Off-label prescribing is another situation

An approved medicine may sometimes be prescribed for a purpose outside its approved label. This is called off-label use and can be medically appropriate. It differs from obtaining a product with no approval at all. The relevant question is what evidence supports that particular use, since FDA approval for one condition does not establish safety and effectiveness for every other purpose. [13]

Turn the offer into a useful conversation

At Healthy Longevity Clinic, our perspective on moving research into care begins with the benefit a person hopes to achieve. Access is useful only when considered together with the evidence and a credible care plan.

Bring these questions to the discussion:

• What exactly is the product, who makes it, and what condition is it intended to treat?

• What happened to comparable patients in studies, including benefits and harms?

• Which trial or access framework applies, and who reviews the proposal?

• Who will monitor me and manage complications, including after I return home?

• What will I pay, and what will insurance cover?

A clear answer will connect the treatment’s legal basis, the evidence for its intended use and the practical plan for your care. That is the foundation for a decision that respects both hope and uncertainty.